Symeres B.V., backed by Keensight Capital, has acquired DGr Pharma, a Netherlands-based consultancy specialised in regulatory strategy and drug development services. The transaction enhances Symeres’ capabilities in early-stage development and strengthens its position as a fully integrated Contract Research, Development and Manufacturing Organisation (CRDMO).

DGr Pharma, founded in 2018, has established itself as a trusted partner for biotechnology and pharmaceutical companies, providing expertise across chemical-pharmaceutical, non-clinical and clinical development, quality assurance, and regulatory submissions. Its services, delivered under GCP and GLP standards, complement Symeres’ existing ADME and drug discovery platforms, thereby offering clients a more streamlined and regulatory-ready pathway to IND submission.

Guillaume Jetten, Chief Executive Officer of Symeres, noted:

“This acquisition strengthens our ability to offer truly integrated solutions across the drug discovery and development spectrum.

Keensight Capital, one of Europe’s leading Growth Buyout investors, supported the acquisition as part of its strategy to further build Symeres’ service offering for its global biopharma client base.

The acquisition is aimed at deepening Symeres’ regulatory expertise, broadening its biopharma capabilities, and accelerating the delivery of transformative therapies from discovery to early clinical development.

Eight Advisory team members supporting this transaction: